The company
ResMed Inc.
RMD · NYSE
RMD stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 36 weeks. It is 11.0% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Above a falling average
- Weeks in an uptrend
- out for 36
- Industry in uptrend
- 27% -9 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $37.5M
- Officials’ trades on record
- 39
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.
Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
39 disclosed lines: House 11, Senate 14, executive 14; 10 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 8 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $50k–$100k | 24 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 23 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 3 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $50k–$100k | 22 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 11 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 28 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
| Alan Armstrong Senate: U.S. Senate eFDSenator | bought | $1k–$15k | 27 Mar 2026filed 21 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 23 Mar 2026filed 14 May 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $100k–$250k | 17 Mar 2026filed 14 May 2026 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Michael J. FarrellChairman and CEO | sold | 4,991at $226.33 | 7 Oct 2026filed 8 Oct 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $222.44 | 8 Sep 2026filed 10 Sep 2026 |
| Peter C. FarrellDirector | sold | 970at $234.73 | 2 Sep 2026filed 4 Sep 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $205.69 | 7 Aug 2026filed 11 Aug 2026 |
| Peter C. FarrellDirector | sold | 8,000at $225.00 | 5 Aug 2026filed 6 Aug 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $218.55 | 7 Jul 2026filed 9 Jul 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $193.96 | 8 Jun 2026filed 9 Jun 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $207.82 | 7 May 2026filed 11 May 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $225.50 | 7 Apr 2026filed 9 Apr 2026 |
| Peter C. FarrellDirector | sold | 2,000at $225.00 | 1 Apr 2026filed 2 Apr 2026 |
| Brett SandercockChief Financial Officer | sold | 1,000at $224.31 | 1 Apr 2026filed 3 Apr 2026 |
| Michael J. FarrellChairman and CEO | sold | 4,991at $251.03 | 9 Mar 2026filed 11 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.